NCT06066333 2026-04-15
Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
Clinical Trials
22 trialsNCT02673333 2026-04-06
Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT06006013 2026-02-18
Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer
Emory University
Phase 2 Recruiting
NCT03333616 2026-01-21
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT06333314 2025-12-02
Pan-MSI-ACSE
UNICANCER
Phase 2 Recruiting
NCT07085572 2025-10-06
INTERVAL
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Phase 2 Recruiting
NCT03127774 2025-10-03
Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma
Columbia University
Phase 2 Recruiting
NCT05634577 2025-06-19
A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT06831175 2025-06-03
Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma
West China Hospital
Phase 2 Recruiting
NCT06587802 2025-04-29
Phase II Study of PD-1 Antibody Combined With Radiotherapy in Recurrent or Metastatic Adrenal Cortical Carcinoma
Sun Yat-sen University
Phase 2 Recruiting
NCT05563467 2025-04-02
PEMBR-01
Maria Sklodowska-Curie National Research Institute of Oncology
Phase 2 Recruiting
NCT03612232 2024-08-19
CaboACC
Wuerzburg University Hospital
Phase 2 Unknown
NCT05913427 2024-08-01
PESETA
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Phase 2 Recruiting
NCT04318730 2024-07-17
Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma
West China Hospital
Phase 2 Recruiting
NCT00453895 2019-01-31
SIRAC
University of Wuerzburg
Phase 2 Completed
NCT00003453 2018-05-09
Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer
Burzynski Research Institute
Phase 2 Terminated
NCT03257891 2018-04-11
CabACC
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Phase 2 Unknown
NCT03145285 2017-05-10
ABACUS
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Phase 2 Unknown
NCT01514526 2017-04-25
Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma
Spanish Oncology Genito-Urinary Group
Phase 2 Completed
NCT00469469 2015-04-22
Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma
Dartmouth-Hitchcock Medical Center
Phase 2 Withdrawn
NCT00324012 2012-02-22
Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma
Rigshospitalet, Denmark
Phase 2 Completed
NCT00786110 2009-02-24
PAXO
University of Turin, Italy
Phase 2 Unknown